- Home
- CORT vs PATH Comparison
CORT vs PATH Comparison
Compare CORT & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- PATH
- Stock Information
- Founded
- CORT 1998
- PATH 2005
- Country
- CORT United States
- PATH United States
- Employees
- CORT N/A
- PATH N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- PATH Computer Software: Prepackaged Software
- Sector
- CORT Health Care
- PATH Technology
- Exchange
- CORT Nasdaq
- PATH Nasdaq
- Market Cap
- CORT 8.1B
- PATH 6.0B
- IPO Year
- CORT N/A
- PATH 2021
- Fundamental
- Price
- CORT $71.68
- PATH $12.48
- Analyst Decision
- CORT Strong Buy
- PATH Hold
- Analyst Count
- CORT 4
- PATH 19
- Target Price
- CORT $142.00
- PATH $13.85
- AVG Volume (30 Days)
- CORT 1.4M
- PATH 12.4M
- Earning Date
- CORT 05-05-2025
- PATH 05-29-2025
- Dividend Yield
- CORT N/A
- PATH N/A
- EPS Growth
- CORT 8.36
- PATH N/A
- EPS
- CORT 1.14
- PATH N/A
- Revenue
- CORT $685,446,000.00
- PATH $1,451,176,000.00
- Revenue This Year
- CORT $35.85
- PATH $8.91
- Revenue Next Year
- CORT $35.22
- PATH $8.99
- P/E Ratio
- CORT $62.77
- PATH N/A
- Revenue Growth
- CORT 30.93
- PATH 7.21
- 52 Week Low
- CORT $28.04
- PATH $9.38
- 52 Week High
- CORT $117.33
- PATH $15.93
- Technical
- Relative Strength Index (RSI)
- CORT 46.01
- PATH 52.01
- Support Level
- CORT $74.34
- PATH $12.09
- Resistance Level
- CORT $80.65
- PATH $14.99
- Average True Range (ATR)
- CORT 3.81
- PATH 0.49
- MACD
- CORT -0.19
- PATH -0.03
- Stochastic Oscillator
- CORT 16.43
- PATH 13.64
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.